|
Apr 6
|
Jim Cramer is Bearish On These 10 Stocks in April
|
|
Apr 6
|
Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock
|
|
Apr 6
|
Is it Too Late to Buy Viking Therapeutics Stock?
|
|
Apr 4
|
How to Create a Stock Portfolio that Pays $100 a Month
|
|
Apr 4
|
3 Growth Stocks with Even Greater Potential Than the Magnificent 7
|
|
Apr 4
|
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
|
|
Apr 4
|
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
|
|
Apr 4
|
LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
|
|
Apr 3
|
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
|
|
Apr 3
|
Lilly's weight-loss drug Zepbound to face supply crunch through April-end, US FDA says
|
|
Apr 3
|
UPDATE 2-Lilly's weight-loss drug Zepbound to face supply crunch through April-end, US FDA says
|
|
Apr 2
|
Dow Jones Futures: Market Holds Key Levels, Meta Eyes Buy Point; Tesla Skids On 'Unmitigated Disaster'
|
|
Apr 2
|
Stocks Bend As Yields Rise; Meta Platforms, Uber, Eli Lilly In Focus
|
|
Apr 2
|
Some doses of Lilly's Mounjaro in tight supply through April, US FDA says
|
|
Apr 2
|
UPDATE 1-Some doses of Lilly's Mounjaro in tight supply through April, US FDA says
|
|
Apr 2
|
FDA website shows limited availability of some doses of Lilly's Mounjaro through April
|
|
Apr 2
|
Eli Lilly’s Ozempic Competitors Face Risks. Why the Stock Has More Upside.
|
|
Apr 2
|
Meta Platforms, AMD Lead 10 Stocks Showing This Bullish Action
|
|
Apr 2
|
Outperforming ETF manager names a potential ‘50-bagger’ in the stock market
|
|
Apr 2
|
The Zacks Analyst Blog Highlights Apple, NVIDIA, Eli Lilly, American Tower and McKesson
|